Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.45 |
| ▸ | NPY2R | P49146 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | TTR | P02766 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | YWHAG | P61981 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | WDR5 | P61964 | 1/20 | 0.42 |
| ▸ | RBP4 | P02753 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31316983 | 0.87 | GFER (0.54) | MAPTTP53SMN1; SMN2AKR1C3NPY2R | |
| SCHEMBL264195 | 0.87 | GFER (0.54) | MAPTTP53SMN1; SMN2AKR1C3NPY2R | |
| SCHEMBL13490136 | 0.84 | HSD11B1 (0.52) | AKR1C3NPY2RTTRWDR5RBP4 | |
| SCHEMBL1368365 | 0.84 | TSHR (0.50) | MAPTTP53SMN1; SMN2CYP3A4SLC9A1 | |
| SCHEMBL28000110 | 0.83 | TTR (0.59) | AKR1C3NPY2RCYP3A4SLC9A1CYP2C19 | |
| SCHEMBL29665792 | 0.83 | NR1H2 (0.51) | MAPTTP53SMN1; SMN2NPY2RALDH1A1 | |
| SCHEMBL265716 | 0.83 | NR1H2 (0.51) | MAPTTP53SMN1; SMN2NPY2RALDH1A1 | |
| SCHEMBL3922259 | 0.81 | MAPT (0.63) | MAPTSMN1; SMN2GFERKDM4EMEN1 | |
| SCHEMBL30501279 | 0.81 | ALDH1A1 (0.44) | MAPTSMN1; SMN2AKR1C3NPY2RCYP3A4 | |
| SCHEMBL31491403 | 0.80 | KDM4E (0.50) | MAPTSMN1; SMN2GFERKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3630778-A1 | NOVEL INHIBITORS OF MAP4K1 | Ichnos Sciences SA (CH) | 2020-04-08 | — | — | EP | disclosed |
| WO-2018215668-A1 | NOVEL INHIBITORS OF MAP4K1 | GLENMARK PHARMACEUTICALS S.A. (CH) | 2018-11-29 | — | — | WO | disclosed |
| WO-2017185034-A1 | DEGRADATION OF CYCLIN-DEPENDENT KINASE 8 (CDK8) BY CONJUGATION OF CDK8 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-10-26 | — | — | WO | disclosed |
| EP-2731953-A1 | TRICYCLIC INHIBITORS OF KINASES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Abbvie Inc. (US) | 2014-05-21 | — | — | EP | disclosed |
| CN-103703005-A | Tricyclic inhibitors of kinases | ABBOTT LAB | 2014-04-02 | — | — | CN | disclosed |
| WO-2013012681-A1 | TRICYCLIC INHIBITORS OF KINASES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ABBOTT LABORATORIES (US) | 2013-01-24 | — | — | WO | disclosed |
| US-7855215-B2 | Cyclic diaryl ureas suitable as tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2010-12-21 | — | — | US | disclosed |
| EP-1951684-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | Targegen, Inc. (US) | 2008-08-06 | — | — | EP | disclosed |
| US-20080039440-A1 | Cyclic Diaryl Ureas Suitable as Tyrosine Kinase Inhibitors | BOLD GUIDO | 2008-02-14 | — | — | US | disclosed |
| WO-2007053452-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039440-A1 | Cyclic Diaryl Ureas Suitable as Tyrosine Kinase Inhibitors | RET, ROS1, BRAF | MAPT 2960/4885TP53 670/4885SMN1; SMN2 2931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.